Basics 2 Flashcards
Drug discovery
Disease target, molecular design/screening, congeners/me too drugs.
Must be tested in animal and human trials, chronic toxicity not usually required
Drug discovery is very expensive and time consuming.
Animal testing: General screening tests for:
pharmacological effects hepatic/renal functioning blood/urine tests gross and histopathologic exams reproductive effects toxicity
What is acute toxicity?
Admin of a single dose of the agent up to lethal dose i at least 2 species. usually 1 rodent and 1 non-rodent
sub ac
What is sub acute toxicity?
2-4 weeks, at least 2 species
What is chronic toxicity?
6-24 mos, at least 2 species
Repro toxicity: what is teratogenic?
Effect on the In Utero Development of an organism resulting in abnormal structure or function-generally not heritable.
Repro toxicity: what is mutagenic?
Effect on the inheritable characteristics of a cell or organism-mutation in DNA.
What is AMES test?A
Standard IN VITRO test for mutagenicity-used for toxicity!
Uses salmonella bacteria, and also used in carcinogenesis test.
What is Dominant Lethal Test?
IN VIVO! test for toxicity. Males are exposedto substance and abnormalities looked for in progeny
FDA approval: Investigational New Drug (IND)
requires animal data, application for FDA approval to carry out new drug trials in humans
FDA approval:New Drug Application (NDA)
Application for FDA approval to market a new drug for ordinary clinical use-requires data from clinical trials as well as animal data.
Clinical Trials: phase I
studies safety of medication and treatment.
20-80 participants
up to several months
Clinical Trials: phase II
Studies the efficacy.
100-300 participants
up to 2 years
Clinical Trials: phase III
Studies safety, efficacy, and dosing.
1-3K participants
1-4 years
Clinical Trials: phase IV
Studies the long-term effectiveness; cost effectiveness.
Thousands of participants
1 yr+
Drug patents:
patent applications usually submitted during animal testing, 20 yrs non competition allowance.
After 20 yrs, generics are allowed into the market, but prove BIOEQUIVALENCE
Orphan Drugs?
Used for rare diseases. Uncommon in R&D b/c cost may not outweigh profit-> may be some federal incentives like grants etc.
Schedule I
No currently accepted medical use in the US. a lack of accepted safety for use under medical supervision, and a HIGH POTENTIAL FOR ABUSE. i.e. heroin, LSD, marajuana,peyote, ecstasy etc
Schedule II
High potential for abuse, may lead to severe psychological or physical dependence. ie codeine, amphetamine, phenobarbitol
Schedule III
Less potential for abuse-moderate to low physical dependence or high psychological dependence. hydrocodone anabolic steroids
Schedule IV
Low potential for abuse relative to schedule III. ie ativan, alprazolam
Schedule V
Low potential for abuse, relative to schedule IV and consists primarily of preparations containing limited qtys of certain narcotics. i.e. cough meds containing no more than 200mg codeine per 100 mL= robitussin
What is an analog?
Drug whose structure is related to another drug. i.e. extra hydrogen, hydroxyl, or methyl group.
Chemical and biological properties may be quite different.
“similar” drugs with similar properties
What is a congener?
substance synthesized by essentially the same synthetic chemical runs and the same procedures as another drug. ie tires. . . .
Congeners and analogs placed into same schedule . ..”designer drugs”
Route of Administration (ROA)
ROA chosen may have profound effect upon the speed and efficiency with which the drug acts. The properties of a drug will determine in which way it can or must be given: solubility, pH effects
Enteral routes-Drugs placed directly into GI tract
Benefits?
Sublingual-placed under tongue Oral-swallowing Buccal-placed in cheek Rectum-absorption through rectum Convenient, outpatient, less expensive
Aspects of Enteral routes: Mouth
thin epithelium
short transit time
most are swallowed and absorbed in GI tract
some absorbed sublingually or buccally
Aspects of Enteral routes: Stomach
Rich blood supply Acid environment Transit time highly variable Some absorption of drug may occur in the stomach, but most reaches intestines Tablet disintegration takes time Some drugs are acid sensitive Irritation develop
Aspects of Enteral routes: Small intestine
Huge SA
ph gradient 4.5-8
Enzyme secretions
Most of drugs absorbed here
Aspects of Enteral routes: Colon
Bacterial actions
Less absorption
Some drugs actually act on the colon
Aspects of Enteral routes: Rectum
Use in unconscious patient or child
Oral Administration advantages include:
Convenient:self-administered, pain free, easy
Absorption:along whole length of GI tract
Cheap:compared to most parenteral routes
Low risk of systemic infections
Antidotes for toxicities and overdose (activated charcoal)
What is the first pass effect?
hepatic metabolism of the drug when it is absorbed through gut an delivered to the liver via the portal circulation. The greater the first pass effect, the less agent will reach systemic circulation when the agent is administered orally
How might reduced liver function affect first pass effect?
More drug will go into circulation!
What are the primary enzymes that will affect first pass metabolism?
GI lumen, Gut wall enzymes, bacterial enzymes, hepatic enzymes
What is bioavailability?
BIOAVAILABILITY= fraction of an administered dose of unchanged drug that reaches the systemic circulation
Oral preparations: what is Enteric coated?
Chemical envelope that resists the action of the fluids and enzymes in the stomach, but dissolve regularly in the upper intestine.
Beneficial for drugs that are acid unstable or irritating to stomach.
Oral preparations: what is extended release?
Special coatings or ingredients that control how fast the drug is released into the body.
Helpful w/ compliance issues; no peaks or troughs